Current Landscape of Treatments for Wolfram Syndrome
Authors:
Open Access
- 1 October 2019
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 40 (10) , 711-714
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (TR002065, TR002345)
- National Institutes of Health (DK112921, DK113487, DK020579)
- JDRF (2-SRA-2016-233-S-N)
This publication has 20 references indexed in Scilit:
- Dominant ER Stress–Inducing WFS1 Mutations Underlie a Genetic Syndrome of Neonatal/Infancy-Onset Diabetes, Congenital Sensorineural Deafness, and Congenital CataractsDiabetes, 2017
- Wolfram Syndrome: Diagnosis, Management, and TreatmentCurrent Diabetes Reports, 2016
- Autosomal Dominant Diabetes Arising From a Wolfram Syndrome 1 MutationDiabetes, 2013
- Wolfram gene (WFS1) mutation causes autosomal dominant congenital nuclear cataract in humansEuropean Journal of Human Genetics, 2013
- Phenotypic characteristics of early Wolfram syndromeOrphanet Journal of Rare Diseases, 2013
- Early Brain Vulnerability in Wolfram SyndromePLOS ONE, 2012
- Identification of p.A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairmentAmerican Journal of Medical Genetics Part A, 2011
- Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cellsJournal of Clinical Investigation, 2010
- Mutations in the Wolfram Syndrome Type 1 Gene (WFS1) Define a Clinical Entity of Dominant Low-Frequency Sensorineural Hearing LossJAMA Otolaryngology–Head & Neck Surgery, 2003
- Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndromeThe Lancet, 1995